CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $59.07, moving -3.46% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.1%.

Tulane University researchers have developed an enhanced CRISPR-based tuberculosis test that works with a simple tongue swab, ...

Researchers have developed a new AI tool to help scientists plan gene-editing experiments. "CRISPR-GPT" can help generate ...

Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced ...

CRISPR Therapeutics (CRSP) has been making waves lately, especially after announcing promising early clinical data for its ...

The new system developed by Professor Chad Mirkin delivers CRISPR machinery more safely and effectively into cells.

CRISPRgenee is a new method that combines gene silencing and cutting to improve loss-of-function studies in human cells.

The model is built on CRISPR technology, a powerful gene editing tool used to edit genomes and develop therapies for genetic diseases. However, training to use this tool for designing experiments can ...

CRISPR-Cas9 technology has revolutionized biotechnology by providing an efficient, precise, and versatile tool for genome editing. This RNA-guided system allows scientists to target specific DNA ...

The U.S. biotechnology market is projected to reach USD 2004.86 billion by 2034, up from USD 699.02 billion in 2025, ...

Scientists study a molecular machine that moves jumping genes in DNA, paving the way for a new gene editing tool beyond ...